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S U M M A R Y
Background: Methicillin-resistant Staphylococcus aureus (MRSA) has now been established as an
important community-acquired pathogen. Although necrotizing pneumonia caused by community-
acquired MRSA (CA-MRSA) strains producing Panton–Valentine leukocidin (PVL) has been reported with
increasing frequency in many countries, it has been reported in only a few children younger than 1 year
of age in Mainland China.
Methods: We describe a case of life-threatening necrotizing pneumonia due to PVL-positive CA-MRSA in
a 15-year-old previously healthy female who presented with high fever, shivering, a dry cough, and
dyspnea. Details of the clinical outcomes, microbiological data, and therapies for this patient were
collected and compared with those of cases reported in the literature on CA-MRSA.
Results: Computed tomography (CT) ﬁndings showed cavitary consolidations in both lungs and bilateral
pleural effusion. MRSA strains isolated from the patient’s sputum and pleural ﬂuid were susceptible to
most non-b-lactam antimicrobial agents except for clindamycin and erythromycin. Both of these
isolates tested positive for the mecA gene as well as PVL genes, and were identiﬁed as ST59-MRSA-
SCCmec type IV-spa type t437. The patient was treated successfully with linezolid, fosfomycin, and
teicoplanin.
Conclusions: To our knowledge, this is the ﬁrst report from Mainland China of necrotizing pneumonia
due to PVL-positive CA-MRSA among those aged older than 1 year. CA-MRSA necrotizing pneumonia
should be considered in the differential diagnosis of severe community-acquired pneumonia,
particularly in previously healthy individuals.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
Contents lists available at ScienceDirect
International Journal of Infectious Diseases
jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Although traditionally regarded as a purely nosocomial
pathogen, methicillin-resistant Staphylococcus aureus (MRSA) has
now emerged as a community-acquired pathogen, affecting
healthy people without recognized risk factors for MRSA acquisi-
tion.1,2 In contrast to traditional healthcare-associated MRSA (HA-
MRSA), these novel MRSA strains, termed community-acquired
MRSA (CA-MRSA), carry smaller staphylococcal chromosomal* Corresponding author. Tel.: +86 10 66936184; fax: +86 10 66936184.
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license (http://creativecommons.org/licenses/by-nc-nd/3.0/).cassette mec (SCCmec) elements (type IV or type V) and retain
susceptibility to a wider range of antimicrobial agents, except for
b-lactams.1–4 Additionally, CA-MRSA strains are more likely than
HA-MRSA strains to carry the Panton–Valentine leukocidin (PVL), a
strong cytolytic factor with a unique ability to create pores in the
cell membranes of human neutrophils and induce the release of
chemotactic factors, although its role in the pathogenesis of CA-
MRSA infections is controversial and PVL-negative CA-MRSA
clones have been reported worldwide in recent years.1,2,5,6
CA-MRSA is primarily associated with skin and soft tissue
infections (SSTIs) in previously healthy individuals;2,7 however, it
may occasionally cause invasive and severe infections like
necrotizing pneumonia, necrotizing fasciitis, pyomyositis, osteo-
myelitis, and sepsis.1,6 As one of the most severe illnesses causedciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Figure 1. CT images at 5 days after the onset of pneumonia, showing irregular consolidations with interspersed small lucent areas in both lungs: A, black arrows; B, white
arrow.
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been reported with increasing frequency in many countries and
has a high mortality rate of 56–63%.1,8 In China, data regarding CA-
MRSA are limited and necrotizing pneumonia caused by PVL-
positive CA-MRSA has been reported in only a few infants.9
Herein, we present a case of life-threatening pneumonia caused
by CA-MRSA with a favorable outcome in a 15-year-old previously
healthy teenage girl. To the best of our knowledge, this is the ﬁrst
report from Mainland China of necrotizing pneumonia due to PVL-
positive CA-MRSA among those aged older than 1 year. We also
review the literature related to CA-MRSA pneumonia.
2. Case report
A 15-year-old previously healthy female presented to the
Chinese People’s Liberation Army General Hospital with a 5-day
history of high fever, sore throat, and a dry cough, as well as a 1-
day history of shivering and dyspnea. She had been diagnosed
with community-acquired pneumonia (CAP) and treated with
intravenous azithromycin in a local hospital for the ﬁrst 4 days.
However, her clinical condition deteriorated rapidly. On the
ﬁfth day, she developed dyspnea requiring oxygen support,
accompanied by shivering and a high fever of 41 8C. A chestFigure 2. CT images at 8 days after the onset of pneumonia, showing multiple cavitary lecomputed tomography (CT) scan showed irregular consoli-
dations with interspersed small lucent areas in both lungs
(Figure 1).
Her vital signs on admission revealed a temperature of 39.9 8C,
heart rate of 102 beats/min, and blood pressure of 140/85 mmHg.
Physical examination showed pharyngeal hyperemia and swelling
of the tonsils. On chest auscultation, lower respiratory sounds and
a few moist rales were heard in the base areas of both lungs. Initial
blood investigations revealed a white blood cell count (WBC) of
10.1  109/l with 94.7% neutrophils and normal hemoglobin and
platelets. Arterial blood gas analysis showed a pH of 7.411, a partial
pressure of carbon dioxide (PaCO2) of 32.9 mmHg, and a partial
pressure of oxygen, arterial (PaO2) of 84.4 mmHg at 9 l/min
inspired oxygen with a partial rebreathing mask. Serum C-reactive
protein (CRP) and procalcitonin (PCT) were both markedly
elevated at 14.2 mg/dl and 26.68 ng/ml, respectively. A PCR test
performed on a nasal swab was negative for inﬂuenza virus. The
patient underwent drainage of the pleural cavity and received a
preliminary diagnosis of empyema. Pleural ﬂuid examination
revealed yellowish purulent features: WBC 2.88  109/l with 90%
neutrophils, lactate dehydrogenase (LDH) 1302.2 IU/l, total protein
(TP) 39.1 g/l, adenosine deaminase (ADA) 33.7 IU/l, glucose
2.4 mmol/l, and chloride 106 mmol/l.sions in both lungs (A, black arrow) and bilateral pleural effusion (B, white arrow).
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with tigecycline was initiated. Three days later, although the serum
CRP and PCT had decreased to 8.3 mg/dl and 1.6 ng/ml, respec-
tively, the patient still had a fever of 39.5 8C and a chest CT scan
revealed multiple cavitary lesions in both lungs and bilateral
pleural effusion (Figure 2). Cultures of sputum and pleural ﬂuid
samples obtained on the day of hospital admission yielded S.
aureus.
3. Methods
Antimicrobial susceptibility testing was performed by broth
dilution method and the results interpreted in accordance with the
Clinical and Laboratory Standards Institute (CLSI) guidelines.
Characterization of SCCmec types and detection of the lukF/lukS
genes encoding PVL were performed as described previously.9
Typing of Staphylococcus protein A (spa) and multilocus sequence
typing (MLST) were performed using established protocols, as
described in the web-based electronic databases http://www.
ridom.de/doc/Ridom_spa_sequencing.pdf and http://saureus.mlst.
net/misc/info.asp.
4. Results
Both of the isolates were resistant to oxacillin (minimal
inhibitory concentration (MIC) 4 mg/l), clindamycin (MIC
256 mg/l), and erythromycin (MIC 256 mg/l), but susceptible
to vancomycin, teicoplanin, linezolid, tigecycline, tetracycline,
fosfomycin, levoﬂoxacin, gentamicin, rifampin, and trimethoprim–
sulfamethoxazole (TMP–SMX). On the basis of culture results,
antimicrobial therapy was changed to intravenous linezolid
(600 mg, every 12 h) and fosfomycin (4 g, every 8 h). Other
supporting therapy was also given to the patient. Twenty days
after the treatment with linezolid and fosfomycin, the patient
showed a signiﬁcant improvement, although she still had an
intermittent fever of 37.5–38 8C. Her CRP decreased to 2.6 mg/dl,
PCT became negative, and leukocyte count was normal. Antimi-
crobial therapy with teicoplanin and fosfomycin was continued for
6 more weeks until her temperature and CRP became normal. At
follow-up 3 months post-discharge, the patient remained in good
health and a CT scan revealed only cord shadow in the lower part of
both lungs. Both of the isolates tested positive for the mecA gene as
well as PVL genes, and were identiﬁed as ST59-MRSA-SCCmec type
IV-spa type t437, which is one of the predominant CA-MRSA clones
in Asian countries.9,10
5. Discussion
MRSA was ﬁrst identiﬁed among hospitalized patients in
196011 and remained a purely nosocomial pathogen causing
serious infections only in individuals with healthcare-associated
risk factors until the late 1980s.6,11 During the 1990s, however,
novel MRSA strains, termed community-acquired MRSA or
community-associated MRSA, began to be reported in community
settings, affecting healthy people without recognized risk factors
for MRSA acquisition.4,6,10 In 2000, the US Centers for Disease
Control and Prevention (CDC) proposed an epidemiological
deﬁnition of CA-MRSA that was based on the timing of the ﬁrst
MRSA isolate relative to hospital admission and the lack of
recognized risk factors for MRSA acquisition.1,4,12 According to the
CDC deﬁnition of CA-MRSA, MRSA must be identiﬁed in the
outpatient setting or at less than 48 h after hospital admission in an
individual with no medical history of MRSA infection or coloniza-
tion, admission to a healthcare facility, dialysis, surgery, or
the insertion of an indwelling device in the past year.4,12
The epidemiological deﬁnition of CA-MRSA has been adoptedworldwide and has been useful for differentiating CA-MRSA strains
from HA-MRSA strains in the past.4 However, as the microbiology
and epidemiology of CA-MRSA have evolved in recent years, purely
epidemiological deﬁnitions of CA-MRSA are breaking down.4,12
Combining epidemiological factors, clinical presentation, the
antimicrobial susceptibility pattern, SCCmec typing, and genotyp-
ing to infer the likely origin of the MRSA may be the best way to
deﬁne CA-MRSA strains at the current time.4 In the present study,
we combined the clinical features, epidemiology, genotyping, and
SCCmec typing to deﬁne the strains isolated from a Chinese
teenager as CA-MRSA.
The presence of CA-MRSA has been reported in many countries
and in different populations, but the prevalence of CA-MRSA varies
geographically.8,13 In some countries and areas, such as the USA,
Taiwan, Canada, and Australia, cases of CA-MRSA infection have
become common.13 A CDC study estimated that in 2005, there
were 94 360 cases of culture-conﬁrmed invasive community-onset
MRSA infections in the USA, with an incidence rate of 31.8/100 000
population.14 However, CA-MRSA remains an uncommon cause of
CAP even in the USA. According to a recent investigation involving
12 American university-afﬁliated emergency departments, the
prevalence of MRSA as the identiﬁed etiology of CAP was 2.4%,
ranging from 0% to 5% by site.15 In Taiwan, CA-MRSA isolates
accounted for 34.8% of community-associated S. aureus infections
according to the ANSORP (Asian Network for Surveillance of
Resistant Pathogens) study.10 However, in other countries and
areas, CA-MRSA infections have been reported only as part of small
outbreaks or case series, and it is usually suspected to have been
imported from regions where the disease is endemic.1
In China, CA-MRSA has not yet become a common pathogen in
the community setting.16 According to surveys on community-
associated SSTIs caused by S. aureus, the prevalence of CA-MRSA
was only 4% among children17 and 3% among adults.18 A recent
study on invasive MRSA infections among hospitalized patients in
Beijing Children’s Hospital (age 14 years), demonstrated that the
incidence of invasive CA-MRSA infections was only 2.43 per 10 000
admissions in 2011.16 In Mainland China, patients with CA-MRSA
pneumonia were ﬁrst reported in 2010.9 Among 55 children with
CA-MRSA pneumonia collected from eight Chinese hospitals
countrywide, only ﬁve aged from 4 to 12 months were diagnosed
with necrotizing pneumonia caused by PVL-positive CA-MRSA.9 In
2011, Li et al.19 reported a case of severe S. aureus CAP carrying the
PVL genes with a favorable outcome in a Chinese adult, however it
did not appear to be an MRSA. To our knowledge, the patient
presented here is the ﬁrst case of necrotizing pneumonia caused by
a PVL-positive CA-MRSA among Chinese school children.
According to their genotypic characteristics, more than 20 CA-
MRSA clones have been reported worldwide, with ﬁve globally
predominant CA-MRSA clones: ST1-IV (USA400), ST8-IV (USA300),
ST30-IV (South West Paciﬁc clone), ST59 (Taiwan clone), and ST80
(European clone).1,2,17 ST1-IV (USA400) was the predominant
clone of CA-MRSA in North America in the late 1990s,1,2 and was
replaced by USA300 after 2000.1 In recent years, PVL-negative ST1
strains have mainly circulated in Australia and England.1,20 ST8-IV
(USA300) is the most prevalent CA-MRSA clone in the USA today
and has been isolated repeatedly in many countries across ﬁve
continents.1 ST30-IV has frequently been isolated all over the
world since it was ﬁrst reported in Australia, New Zealand, and
West Samoa.1,17 In Australia, Asia, South America, Europe, and the
Middle East, ST30-IV is currently among the predominant clones of
CA-MRSA.1,17,21 ST80 is the most common clone of CA-MRSA in
many Western European countries, and has also occasionally been
found in other parts of the world, including Australia, Kuwait,
Tunisia, and Malaysia.1,17 ST59 is the primary CA-MRSA clone in
Taiwan and several other Asian countries, and has also been
recovered from patients in Australia, Europe, and the USA.1,10,17
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the ST59-MRSA-SCCmec type IV-spa t437 clone. A recent ANSORP
study involving eight Asian countries or regions demonstrated
ST59-MRSA-SCCmec type IV-spa t437 to be the predominant clone
in Taiwan, Hong Kong, Vietnam, and Sri Lanka.10 ST59-MRSA-
SCCmec type IV-spa t437 has also been veriﬁed to be the most
prevalent CA-MRSA clone among children with SSTIs or uncom-
plicated pneumonia in Mainland China.12,17,22 However, ST59-
MRSA-SCCmec type IV-spa t437 has never before been reported to
cause severe necrotizing pneumonia in Mainland China. Among
ﬁve Chinese children with necrotizing CA-MRSA pneumonia
reported in 2010, there were three clones responsible for the
CA-MRSA infections, including ST910-MRSA-SCCmec type IV-spa
t318, ST398-MRSA-SCCmec type V-spa t034, and ST1409-MRSA-
SCCmec type IV-spa t653.12
In comparison with HA-MRSA strains, CA-MRSA strains are
typically susceptible to most non-b-lactam antimicrobial agents in
many countries. However, increasing non-b-lactam resistance
among CA-MRSA strains has been reported repeatedly in recent
years.22 Some studies have shown the resistance rates of CA-MRSA
isolates to non-b-lactam agents to vary between countries and
clones.1,23 In the USA, USA300 strains are usually resistant to
erythromycin, while USA400 strains are often resistant to both
erythromycin and clindamycin.23,24 In Europe, ST80-IV strains are
typically resistant to tetracycline and fusidic acid.23,25 In Australia,
the three predominant CA-MRSA clones, including ST30-MRSA-IV,
ST93-MRSA-IV, and ST1-MRSA-IV, are often uniformly susceptible
to almost all non-b-lactams.20,23 In Asia, ST30-MRSA-SCCmec type
IV-spa type019 strains and ST72-MRSA-SCCmec type IV-spa type
t324 strains are often susceptible to non-b-lactams, but ST59-
MRSA-SCCmec type IV-spa type t437 strains have shown multiple
resistance to several non-b-lactam agents, including erythromy-
cin, clindamycin, tetracycline, and gentamicin.12,22,23
Although severe necrotizing pneumonia caused by CA-MRSA is
still rare in Mainland China, invasive CA-MRSA infections have
increased signiﬁcantly in recent years.16 Clinicians should be
aware that CA-MRSA can lead to lethal pneumonia even in
previously healthy people. Necrotizing pneumonia is one of the
most severe manifestations of CA-MRSA infection and has a rapidly
progressive and fatal course.8,26 Early recognition of this life-
threatening infection and appropriate antimicrobial treatment are
crucial for improving the prognosis.26,27 It is well established that
CA-MRSA should be suspected as the cause of pneumonia if the
following speciﬁc features are present: an inﬂuenza-like pro-
drome; severe respiratory symptoms with a rapidly progressive
pneumonia evolving to acute respiratory distress syndrome; fever
>38–39 8C; hemoptysis; hypotension; leukopenia; chest radio-
graph showing multi-lobular inﬁltrates, which may have cavitat-
ed; known colonization with CA-MRSA or recent travel to an
endemic area, such as North America, and recent contact with CA-
MRSA; belonging to a group associated with increased rates of
colonization with CA-MRSA; previous history or family history of
recurrent furuncles or skin abscesses.28 Appropriate cultures of
blood, sputum, and pleural ﬂuid specimens are essential for
prompt diagnosis and should be performed prior to the initiation of
empirical antimicrobial therapy.29 Although CA-MRSA isolates are
often susceptible to many non-b-lactam agents in vitro, the
Infectious Diseases Society of America (IDSA) recommends
vancomycin, linezolid, or clindamycin as ﬁrst-line drugs for the
treatment of CA-MRSA and HA-MRSA pneumonia.30 However,
since high resistance rates to clindamycin in CA-MRSA strains have
been reported repeatedly in China,12,16,17 clindamycin should not
be used alone in the treatment of CA-MRSA pneumonia in China
unless a CA-MRSA strain susceptible to clindamycin has been
isolated from the patient.To our knowledge, this is the ﬁrst report from Mainland China of
necrotizing pneumonia due to PVL-positive CA-MRSA among those
aged older than 1 year. Since invasive CA-MRSA infections have
increased signiﬁcantly in China in recent years, CA-MRSA
necrotizing pneumonia should be considered in the differential
diagnosis of severe CAP, particularly in previously healthy
individuals.
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